Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Mar 14, 2023 6:18pm
259 Views
Post# 35338546

Re Future !!

Re Future !!Quote:
"Probably  the real defining factor is the result of the Sheido trial.

If the outcomes were not great  then there is no incentive to make a deal.   If that is the case then Replicel  would have to try to get  some  trials done on the other two possible products which  will stretch this  out  for a long  time

How  much time  does  Andrew  have??  He  is the only one really  'bucking-up'.    Seems he has  more confidence than anyone else."

I agree there is much riding on the results of the current Shiseido Trial.  My read is the results are in and if as you say "were not great" I think Shiseido would not be persisting in this Arbitration. Rather they would not be fighting for something they will not be pusrsuing.  I think actually the results are encouraging enough for them to consider taking the technology to market and as we all know it is a very big market.  

I have said it before many times I think with so much riding on this Shiseido will be coming to the bargaining table to work out a deal with Replicel before the hearing.  I am not  sure what is holding this up as we are now 2 1/2 months away from the hearing and any sort of deal negotiation will take some time. 

As for your comment about Andrew Schutte and his deep pockets, there is no doubt he is all in on this and stands to make some considerable money if things go Replicel's 
way. The other big investor is Jamie Mackay who seems to hold at least 7,000,000+ shares.  Both these individuals have increased their positions greatly in the past year. 
That alone keeps me believing !







<< Previous
Bullboard Posts
Next >>